Stocks like Moderna and Novovax have enjoyed sharp rallies in the swirl of coverage about Covid-19 vaccines. Missing from the action to date has been Johnson & Johnson, which has quietly developed another messenger RNA vaccine to join those already approved and in circulation. Johnson & Johnson's vaccine only requires one shot, which could make it easier to distribute in large quantities, faster.
Results from a large clinical trial just hit the tape this week, with Johnson & Johnson's vaccine proving 66% effective at protecting people from moderate to severe disease. While this number is lower than previous efficacy rates published by the likes of Moderna and Pfizer-BioNTech, Johnson & Johnson's figures may be lower due to the existence of new strains of the coronavirus. Nevertheless, experts stay the vaccine should still provide strong protection.
So where does JNJ's stock stand as it prepares to obtain approval for its vaccine shot? Is it a potential buy as investors rotate to new vaccine makers just hitting the market? Tickeron's A.I. digs into the issue below, running a deep analysis on six Covid-19 vaccine plays.